Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the effect of skin antisepsis and/or emollient therapy on bacterial colonization dynamics in very low birth weight, hospitalized infants. Bacterial swabs from 5 body sites will be collected at baseline, day 3, day 8 and day 13 following study arm assignment. Study outcomes include changes in bacterial colony counts, burden of gram-negative and gram-positive pathogens and overall skin score.


Clinical Trial Description

Despite substantial global decline in childhood mortality rates, equivalent progress in neonatal mortality reduction has not been achieved. Severe bacterial infection affects approximately 6.9 million neonates and causes an estimated 750 000 deaths in low-middle income countries (LMIC) annually. The neonatal period extends from birth to 28 days of life, although neonatal hospitalization episodes (and therefore infection risk) are often substantially prolonged in preterm infants. In South Africa, infections account for 13.8% of neonatal mortality (following prematurity and intrapartum hypoxia). The South African Perinatal Problem Identification Programme (PPIP) cites nosocomial infection as the second most prevalent avoidable factor in neonatal deaths. Developing new approaches to prevent infection in hospitalized and preterm newborns in LMIC is key to achieving the Sustainable Development targets for under-five child survival.

The risk for hospital-onset sepsis in African neonates is disproportionately high and influenced by many factors including: high rates of prematurity and low birth weight; increasing in-hospital births, understaffing of maternity and neonatal services and limited implementation of infection prevention practices. Of infections among hospitalized neonates in high-income settings, hospital-acquired bloodstream infections (HA-BSI) predominate, accounting for 57% of infections. Research addressing the problem of hospital-onset neonatal infection should therefore focus on BSI prevention. A key target for sepsis reduction is prevention of intrapartum and post-delivery acquisition of bacterial colonization. Although the pathogenesis of bacterial colonization preceding invasive infection is well-accepted, there is limited data describing neonatal bacterial colonization dynamics in low-resource settings. Full characterization of timing, source and route of bacterial acquisition, flora/pathogen distribution, balance and changes over time is needed to identify all potential targets for neonatal BSI prevention.

Emollient therapy and reduction of pathogen colonization through skin antisepsis, are potentially useful targets for reducing risk of hospital-acquired BSI in neonates. Emollients (oils, creams and ointments) have been applied daily or bi-daily in neonatal research and routine practice settings, to promote skin integrity in preterm infants <37 weeks' gestation. The postulated mechanism of effect is improved skin barrier function and promotion of normal flora colonization, which may prevent pathogen ingress and subsequent invasive infection. A 2016 Cochrane review of emollient therapy for sepsis prevention in preterm infants found no evidence of reduced mortality or bloodstream infection rates, but the authors concluded that further studies in low-resource settings were warranted.

Chlorhexidine gluconate (CHG) is a bisbiguanide molecule with broad-spectrum antiseptic activity producing membrane disruption through increased cell permeability and bacterial lysis. Efficacy and safety of daily CHG bathing to prevent pediatric bacteremia was established in a multicenter, cluster-randomized trial for infants >2 months in intensive care (ICU) using 2% CHG-impregnated cloths. Three high-quality studies of newborn CHG skin or cord cleansing showed reduced neonatal mortality and omphalitis in community-based neonates. Safety of topical CHG application for neonates has been established at concentrations ≤1%, although there is little data available on its use in premature, hospitalized neonates.

CHG skin cleansing and emollient therapy are potentially useful interventions for prevention of hospital-acquired BSI in neonates from low-resource settings. In addition, these interventions are suitable for inclusion in a neonatal sepsis prevention care bundle, should they be found to be effective, safe and feasible. In addition these interventions would be low-cost, easily scalable and potentially, a maternally-administered intervention. This study will evaluate the effect of skin antisepsis and/or emollient therapy on bacterial colonization dynamics in very low birth weight, hospitalized infants. Bacterial swabs from 5 body sites will be collected at baseline, day 3, day 8 and day 13 following study arm assignment. Study outcomes include changes in bacterial colony counts, burden of gram-negative and gram-positive pathogens and overall skin score. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03896893
Study type Interventional
Source University of Stellenbosch
Contact Angela Dramowski, MD, PhD
Phone +27219389506
Email dramowski@sun.ac.za
Status Recruiting
Phase N/A
Start date March 4, 2019
Completion date September 30, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03670732 - CPAP vs.Unsynchronized NIPPV at Equal Mean Airway Pressure N/A
Completed NCT05322161 - Yoga in the NICU for Parents Study N/A
Recruiting NCT04542096 - Real Time Evaluation of Dynamic Changes of the Lungs During Respiratory Support of VLBW Neonates Using EIT
Recruiting NCT04911452 - Creating a Calmer NICU: Optimizing Growth and Brain Development in Preterm Infants N/A
Recruiting NCT02901652 - NIPPV and nBiPAP Methods in Preterm Infants With Respiratory Distress Syndrome N/A
Completed NCT02148965 - Effects of Exercise During Pregnancy on Maternal and Child Health: a Randomized Clinical Trial N/A
Terminated NCT02032511 - Comparison of RAM Cannula Nasal Continuous Positive Airway Pressure Versus Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP) N/A
Completed NCT02273843 - A Trial on Different Dosages of Vitamin D in Preterm Infants With Late-onset Sepsis Phase 1
Completed NCT01721629 - Weaning of Nasal Continuous Positive Airway Pressure (CPAP) in Premature Infants N/A
Terminated NCT01819532 - Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants < 33 Weeks N/A
Completed NCT01523769 - Umbilical Cord Milking on the Reduction of Red Blood Cell Transfusion Rates in Infants N/A
Completed NCT01478711 - Comprehensive Clinical Decision Support (CDS) for the Primary Care of Premature Infants N/A
Completed NCT00951860 - Assessment of Autonomic Maturation in Neonatal Period and Early Neural Development From a Longitudinal Prospective Cohort N/A
Completed NCT00749008 - Study of Generalized Movements for Early Prediction of Cerebral Palsy N/A
Completed NCT00787124 - Transfusions and Nitric Oxide Level in Preterm Infants
Terminated NCT00486395 - Will CPAP Reduce Length Of Respiratory Support In Premature Infants? Phase 3
Completed NCT00527956 - Facilitation and Barriers to Breastfeeding in the NICU N/A
Terminated NCT01208493 - Dietary Protein in the Very-low-birth-weight Infant N/A
Completed NCT03372590 - NEO Rehab for Infants at Risk of Cerebral Palsy N/A
Completed NCT00033917 - Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial Phase 3